IVIG Infusion Therapy in New York

IVIG is not one product with one label. It is a class of pooled human immunoglobulin products, and each brand carries its own FDA-approved indications. Nearly every product is approved for primary immunodeficiency; only some are approved for chronic immune thrombocytopenic purpura or chronic inflammatory demyelinating polyneuropathy (CIDP); and three indications belong to a single product each. The table below reflects the current approved labeling for the products most often prescribed. It is the reason a prescription for IVIG names a specific product rather than the class.

Off-label use, stated plainly: no FDA-licensed immunoglobulin product carries an approved indication for myasthenia gravis, Guillain-Barre syndrome, autoimmune encephalitis or stiff person syndrome. IVIG is used in these conditions off-label, with professional-society consensus supporting some of them more strongly than others. The American Academy of Neurology's 2012 evidence-based guideline on IVIG in neuromuscular disorders has since been retired by the AAN; the current professional document is the 2023 updated consensus statement of the American Association of Neuromuscular & Electrodiagnostic Medicine (Tavee et al., Muscle & Nerve, doi:10.1002/mus.27922). Ask the prescribing neurologist which recommendation applies to your diagnosis.

FDA maintains the full list of licensed immune globulin products in the United States on its approved immune globulins page.

IVIG dosing is weight-based and falls into two very different ranges. Replacement dosing, used when the body does not make enough antibodies, runs 300 to 600 mg/kg every three to four weeks on most labels, with several products labeled higher — Privigen at 200 to 800 mg/kg and Bivigam at 300 to 800 mg/kg. The Immune Deficiency Foundation describes a typical starting dose of 400 to 600 mg/kg per month. Immunomodulatory dosing, used to change how an overactive immune system behaves, is several times higher: 2 g/kg for chronic ITP, and a 2 g/kg loading dose followed by 1 g/kg every three weeks for CIDP.

Because dosing is calculated in mg/kg, an accurate weight in kilograms is recorded before every infusion — Medicare lists this as a documentation requirement, not an optional step.

The Immune Deficiency Foundation states that IVIG infusions typically take between two and six hours. A first infusion sits at the long end, and the reason is in the labeling: every IVIG product prescribes a stepwise rate escalation that starts low and increases only if tolerated. Gamunex-C for primary immunodeficiency starts at 1 mg/kg/min and rises to a maximum of 8 mg/kg/min; Octagam 10% for dermatomyositis is capped at 0.04 mL/kg/min because of thromboembolic risk. The Immune Deficiency Foundation notes that a first-time administration rate should be slower than the recommended rate and then increased to a rate the patient tolerates.

A high-dose course is also often not a single visit. A 2 g/kg dose is labeled as divided over two consecutive days for chronic ITP and over two to five days for CIDP loading and for dermatomyositis. Our guide to a first IVIG infusion covers what that means for planning a day.

Every IVIG product carries an FDA boxed warning headed "WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE". The warning names risk factors for thrombosis — advanced age, prolonged immobilization, hypercoagulable conditions, prior venous or arterial thrombosis, estrogen use, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors — and then states that thrombosis may occur in the absence of known risk factors. It also directs clinicians to ensure adequate hydration before administration and to use the minimum dose, concentration and infusion rate practicable in patients at risk.

Two points are commonly got wrong elsewhere and are worth stating precisely. First, the renal portion of the boxed warning applies to intravenous immunoglobulin; subcutaneous products such as Hizentra carry the thrombosis warning only. Second, aseptic meningitis, hemolysis and transfusion-related acute lung injury are Warnings and Precautions, not boxed warnings — they are real and they are monitored for, but describing them as boxed warnings misstates the label.

On frequency, the Immune Deficiency Foundation reports that systemic side effects occur in up to 34% of IVIG infusions and that about 1% result in serious systemic side effects. The most common are headache, nausea or vomiting, fever or chills, flushing, wheezing, back, muscle or joint aches, and chest tightness. Incidence is strongly dose-dependent: in the Gamunex-C trials, headache was reported by 14.9% of the primary immunodeficiency population at replacement dosing, 31.0% of the CIDP population, and 52.1% of the chronic ITP population — the same drug at three different doses. In a review of immunoglobulin adverse effects, Guo et al. (Frontiers in Immunology, 2018) put aseptic meningitis at 0.6 to 1% of patients and noted that slowing the infusion rate can greatly reduce the rate of adverse reactions.

Prime Infusions administers IVIG at its infusion centers across New York City, Long Island and the Hudson Valley, plus one center in Atlanta. In New York that means Brooklyn and Boro Park; Fresh Meadows, Astoria, Jamaica and Howard Beach in Queens; the Upper East Side in Manhattan; Staten Island; Great Neck in Nassau County and Inwood in the Five Towns; Port Jefferson Station in Suffolk County; and New City in Rockland County and Monroe in Orange County. The full list, with addresses, is on our locations page.

Site of care is not only a convenience question — commercial payers now express a preference. UnitedHealthcare's commercial site-of-care policy effective 1 August 2026 names IVIG and subcutaneous immunoglobulin explicitly and states that non-hospital outpatient infusion, physician offices, ambulatory infusion suites and home infusion are well accepted places of service for medication infusion therapy, approving hospital outpatient administration only on specific criteria and reassessing that approval at six months. Whether any particular plan applies that policy to a particular patient is a determination only that plan can make.

IVIG requires prior authorization from essentially every payer, and the requirements are specific. Using Aetna's Clinical Policy Bulletin 0206 as a worked example of commercial criteria (last reviewed 18 June 2026): primary antibody deficiencies require a pretreatment IgG below 200 mg/dL for severe combined immunodeficiency or agammaglobulinemia, or below 500 mg/dL or at least two standard deviations below the mean for age for common variable immunodeficiency, plus an impaired antibody response to pneumococcal polysaccharide vaccine — the element most often missing from a submission. CIDP requires a progressive or relapsing course of two months or longer and electrodiagnostic confirmation. Continuation requires a documented reduction in bacterial infections and IgG trough levels monitored at least yearly, at the lowest effective dose and frequency.

Medicare adds its own documentation set: a history and physical with the physician's rationale current within the last twelve months, an order not more than 30 days old specifying dose, frequency and route, ICD-10 codes supporting medical necessity on each claim, and a weight in kilograms recorded before each infusion.

Prime Infusions verifies benefits and submits the authorization request together with the prescribing physician. No infusion provider can promise an approval — coverage, prior authorization and out-of-pocket cost are determined solely by the health plan. Our guide to IVIG prior authorization in New York covers the documentation in detail, along with the state step-therapy override and external appeal deadlines.

Both are possible, and they are different questions. Home intravenous administration is a setting decision. Medicare covers home IVIG items and services under Social Security Act section 1861(zz), made permanent by section 4134 of the Consolidated Appropriations Act, 2023 from 1 January 2024 — but only for patients with a diagnosed primary immune deficiency disease whose treating practitioner has determined home administration is medically appropriate. It does not extend to CIDP, ITP, multifocal motor neuropathy or dermatomyositis. Prime Infusions also offers home infusion services outside that benefit.

Subcutaneous immunoglobulin is a different route, not a different location. It is given more frequently in smaller volumes, typically over one to two hours, and produces steadier IgG levels rather than the peak-and-trough pattern of monthly IVIG: Beydoun et al. (Frontiers in Neurology, 2021) report subcutaneous peaks at around 60% of the typical post-IVIG peak, reached after 36 to 72 hours, with troughs 12 to 15% higher than monthly IVIG. Hizentra and HyQvia are both labeled for CIDP maintenance therapy in adults. Our comparison of IVIG and SCIG sets out the trade-offs. Which route is appropriate is a decision for the prescribing clinician, constrained by what each product is actually labeled for.

Patients receiving IVIG often experience significant improvements in their condition, such as enhanced immune function, reduced nerve damage, and relief from autoimmune symptoms. IVIG can be life-changing for those with chronic conditions that affect the immune system, offering both symptom relief and a better quality of life. The infusion process is typically done every few weeks, depending on the patient’s condition and response to treatment.